The Synthetic-Technical Development of Oseltamivir Phosphate Tamiflu™: A Race against Time

The clinical development of the first orally available neuraminidase inhibitor prodrug oseltamivir phosphate (Tamiflu™) proceeded very fast. In order to support this program an unprecedented team effort in chemical process research, development, piloting, production and analytics took plac...

Full description

Bibliographic Details
Published in:CHIMIA
Main Authors: Stefan Abrecht, René Trussardi, Gösta Rimmler, Thomas Oberhauser, Hans-Jürgen Mair, Martin Karpf, Rolf Fischer, Heinrich Estermann, Muriel Cordon Federspiel, Ulrich Zutter
Format: Article
Language:German
Published: Swiss Chemical Society 2007-03-01
Subjects:
Analytics
Influenza neuraminidase inhibitor
Oseltamivir phosphate
Production
Synthesis
Technical development
Online Access:https://chimia.ch/chimia/article/view/4283
Description
Summary:The clinical development of the first orally available neuraminidase inhibitor prodrug oseltamivir phosphate (Tamiflu™) proceeded very fast. In order to support this program an unprecedented team effort in chemical process research, development, piloting, production and analytics took place, which allowed the successful launch of Tamiflu™ in 1999, only two and a half years after it was licensed from Gilead Sciences. This article describes selected aspects of the commercially used synthesis route and a brief summary of alternative syntheses devised by Roche chemists.
ISSN:0009-4293
2673-2424

Similar Items